The effectiveness of methylphenidate in the management of Attention Deficit Hyperactivity Disorder (ADHD) in people with intellectual disabilities: a systematic review

Research output: Contribution to journalArticle

Standard

The effectiveness of methylphenidate in the management of Attention Deficit Hyperactivity Disorder (ADHD) in people with intellectual disabilities : a systematic review. / Tarrant, Nick; Roy, Meera; Deb, Shoumitro; Odedra, Smita; Retzer, Ameeta; Roy, Ashok.

In: Research in Developmental Disabilities, Vol. 83, 12.2018, p. 217-232.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{fe4b68fbcb364653b9873516d6875ac8,
title = "The effectiveness of methylphenidate in the management of Attention Deficit Hyperactivity Disorder (ADHD) in people with intellectual disabilities: a systematic review",
abstract = "BACKGROUND: The effectiveness of psychostimulants, primarily methylphenidate (MPH), in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in the general population of typically growing children and adolescents is well established through many Randomised Controlled Trials (RCTs).AIMS AND METHODS: We carried out a systematic review of all the RCTs in people with intellectual disabilities (ID) that assessed effectiveness of MPH on the core ADHD symptoms.OUTCOMES AND RESULTS: We included 15 papers from 13 studies that were all on children and adolescents with ID (315 participants were on MPH and placebo respectively), 12 of which used a cross over design, and one used a parallel design. On average around 40-50% responded to MPH in the ID group whereas around 70-80% response rate is reported among the non-ID children. Because of the heterogeneity of the outcome data it was not possible to carry out a meta-analysis. Significant adverse events included sleep difficulties and poor appetite along with weight loss and also irritability, social withdrawal and increased motor activities including tic.CONCLUSIONS AND IMPLEMENTATION: On the basis of the poor quality evidence that is available, it seems that MPH may be effective in some but not all children and adolescents with ID and ADHD.",
keywords = "Intellectual disabilities, ADHD, Methylphenidate, Treatment, Child and adolescents",
author = "Nick Tarrant and Meera Roy and Shoumitro Deb and Smita Odedra and Ameeta Retzer and Ashok Roy",
note = "Copyright {\textcopyright} 2018 Elsevier Ltd. All rights reserved.",
year = "2018",
month = dec
doi = "10.1016/j.ridd.2018.08.017",
language = "English",
volume = "83",
pages = "217--232",
journal = "Research in Developmental Disabilities",
issn = "0891-4222",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - The effectiveness of methylphenidate in the management of Attention Deficit Hyperactivity Disorder (ADHD) in people with intellectual disabilities

T2 - a systematic review

AU - Tarrant, Nick

AU - Roy, Meera

AU - Deb, Shoumitro

AU - Odedra, Smita

AU - Retzer, Ameeta

AU - Roy, Ashok

N1 - Copyright © 2018 Elsevier Ltd. All rights reserved.

PY - 2018/12

Y1 - 2018/12

N2 - BACKGROUND: The effectiveness of psychostimulants, primarily methylphenidate (MPH), in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in the general population of typically growing children and adolescents is well established through many Randomised Controlled Trials (RCTs).AIMS AND METHODS: We carried out a systematic review of all the RCTs in people with intellectual disabilities (ID) that assessed effectiveness of MPH on the core ADHD symptoms.OUTCOMES AND RESULTS: We included 15 papers from 13 studies that were all on children and adolescents with ID (315 participants were on MPH and placebo respectively), 12 of which used a cross over design, and one used a parallel design. On average around 40-50% responded to MPH in the ID group whereas around 70-80% response rate is reported among the non-ID children. Because of the heterogeneity of the outcome data it was not possible to carry out a meta-analysis. Significant adverse events included sleep difficulties and poor appetite along with weight loss and also irritability, social withdrawal and increased motor activities including tic.CONCLUSIONS AND IMPLEMENTATION: On the basis of the poor quality evidence that is available, it seems that MPH may be effective in some but not all children and adolescents with ID and ADHD.

AB - BACKGROUND: The effectiveness of psychostimulants, primarily methylphenidate (MPH), in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in the general population of typically growing children and adolescents is well established through many Randomised Controlled Trials (RCTs).AIMS AND METHODS: We carried out a systematic review of all the RCTs in people with intellectual disabilities (ID) that assessed effectiveness of MPH on the core ADHD symptoms.OUTCOMES AND RESULTS: We included 15 papers from 13 studies that were all on children and adolescents with ID (315 participants were on MPH and placebo respectively), 12 of which used a cross over design, and one used a parallel design. On average around 40-50% responded to MPH in the ID group whereas around 70-80% response rate is reported among the non-ID children. Because of the heterogeneity of the outcome data it was not possible to carry out a meta-analysis. Significant adverse events included sleep difficulties and poor appetite along with weight loss and also irritability, social withdrawal and increased motor activities including tic.CONCLUSIONS AND IMPLEMENTATION: On the basis of the poor quality evidence that is available, it seems that MPH may be effective in some but not all children and adolescents with ID and ADHD.

KW - Intellectual disabilities

KW - ADHD

KW - Methylphenidate

KW - Treatment

KW - Child and adolescents

U2 - 10.1016/j.ridd.2018.08.017

DO - 10.1016/j.ridd.2018.08.017

M3 - Article

C2 - 30266025

VL - 83

SP - 217

EP - 232

JO - Research in Developmental Disabilities

JF - Research in Developmental Disabilities

SN - 0891-4222

ER -